Cell and gene therapy-focused OpenCell Technologies hires MilliporeSigma executive Kevin Gutshall as new CEO – Webster County Citizen

ST. LOUIS, June 18, 2020 /PRNewswire/ -- OpenCell Technologies, an R&D-stage biomedical venture, has announced the hiring of Kevin Gutshall as CEO. Kevin leaves his role as MilliporeSigma's director of life science business development and M&A focusing on the cell and gene therapy business unit, to join OpenCell and lead its efforts to translate and commercialize its core technology platform, POROS.

OpenCell was established based on technology developed at the Georgia Institute of Technology, by Engineering faculty and company co-founders Mark Meacham, PhD, Andrei Fedorov, PhD, and Levent Degertekin, PhD. Dr. Meacham was subsequently recruited to Washington University in St. Louis, and OpenCell relocated to the BioGenerator Labs in the Cortex Innovation Community adjacent to the Washington University School of Medicine. The company's core technology, which has broad applications ranging from fuel and energy to life sciences, is focused on the rapidly emerging cell and gene therapy market.

"I am thrilled to join OpenCell, as it is now poised to move from an R&D stage to a commercial business," said Gutshall. "I believe that the POROS platform will be a disruptive technology platform in the cell and gene therapy marketplace."

During its seed stage, the company benefitted from BioGenerator Entrepreneurs-in-Residence (EIR) that brought key expertise to the company as it pivoted from the research tools market to cell and gene therapy applications. Paul Olivo, MD, PhD, a former BioGenerator EIR and current Venture Partner at Synchrony Bio, which also participated in the current financing, serves as a key advisor to OpenCell, managing the company's research team. In her role as BioGenerator EIR, Heather Holeman, PhD, now CEO of Lifespan Biosciences, facilitated key business development connections for the company. Concurrent with the financing, Charlie Bolten, Senior Vice President of BioGenerator, joins OpenCell's board of directors.

"Together with Synchrony Bio, BioGenerator's investment in OpenCell is the culmination of extensive due diligence and hands-on support by our investment, Entrepreneur-in-Residence and Grants-2-Business teams," said Bolten. "With the successful recruitment of a CEO with deep experience in commercialization, business development and M&A, we are pleased to see OpenCell take an important step toward commercializing the POROS platform."

"I am excited to welcome Kevin as the new CEO of OpenCell," added Chad Stiening, OpenCell Executive Chairman and Managing Director at Synchrony Bio. "His professional background and personal passion in the cell and gene therapy space is a perfect fit for the company as it seeks to realize the full potential of its technology and enable the development and manufacturing of promising new therapies in this dynamic market."

In addition to investments from BioGenerator and Synchrony Bio, the company has leveraged significant Federal grant funding over $3M total to help secure equity financing and achieve key milestones that helped attract strategic partnering interest as well as its new CEO.

About OpenCellOpenCell Technologies provides efficient, high-throughput and scalable transfection tools to the Life Science Industry, enabling it to use difficult-to-transfect cells (e.g., primary and cancer stem cell cultures) in development of cell-based analysis techniques and discovery of new therapeutic cell-based therapies. Unlike currently available products, the OpenCell technology features precise control of biophysical actions on a single-cell basis without sacrificing throughput. OpenCell's vision is to realize a novel, cost-effective approach to transfection that will overcome existing research and development obstacles.Our mission is to make cellular therapies effective, affordable and scalable for the clinical and research communities. Visit opencelltech.com for more information.

About BioGenerator BioGenerator, the investment arm of BioSTL, produces a sustained pipeline of successful bioscience companies and entrepreneurs in St.Louis by creating, growing and investing in promising new enterprises. Visit biogenerator.org for additional information, and follow us on LinkedIn and Twitter.

About Synchrony BioSynchrony Bio seeks to achieve consistently superior investor returns in early-stage biomedical and life science ventures by aligning seasoned talent, staged investment capital, and process efficiencies.Careful and coordinated alignment of all three is key to overcoming unique challenges faced by medical device and diagnostics ventures, in order to realize significant upside and superior returns.Synchrony's extended network of experts and advisors includes professionals with deep, cross-functional experience and backgrounds. Visit synchronybio.com for additional information.

Go here to read the rest:
Cell and gene therapy-focused OpenCell Technologies hires MilliporeSigma executive Kevin Gutshall as new CEO - Webster County Citizen

COVID 19 Impact on REGENERATIVE MEDICINE MARKET 2020 GLOBAL INDUSTRY SIZE, ANALYSIS, FUTURE GROWTH, TYPES, END-USERS, KEY PLAYERS AND REGIONAL…

The Global Regenerative Medicine Market increasing adoption of stem cell technology, growing prevalence of chronic diseases, and emerging applications of gene therapy in regenerative medicine are some of the driving factors for the global regenerative medicine market.A number of factors, such as the government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population are expected to drive the growth of this market. Click to Access Sample Pages @https://www.orianresearch.com/request-sample/722408Ethical concerns with the use of embryonic stem cell for r&d, lack of clear regulatory guideline are some of major factors which can hamper the growth of the market.

Rising Demand for Organ Transplantation and Strong Product Pipeline are some of the opportunitites in the forecast period.

Based on therapy the market is segmented into cell therapy, gene therapy, tissue engineering, immunotherapy. The cell-based products is expected to dominate the global Regenerative Medicine market in 2016. Increasing funding from several agencies and private organizations for the research and development of cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness about the benefits of stem cell therapies are driving the growth of the cell therapy segment.

Based on application the market is segmented into, Orthopedic & Musculoskeletal Disorders, Dermatology, Oncology, Cardiology

North America dominates the regenerative medicine market due to rapid technological advancements and high investment & funding to support development of regenerative medicine. Asia-Pacific is also expected to propel the regenerative medicine market, owing to factors, such as increasing accessibility to healthcare facilities in the region, and surging economic growth.

Some of the key players operating in this market includeOrganogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.). The key players in the acellular products segment are Medtronic (Ireland), Acelity (KCI Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), and C.R. Bard (U.S.).

Key Benefits of the Report:

* Global, Regional, Country, Therapy, and APPLICATION Market Size and Forecast from 2014-2025

* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies

* Identification of key companies that can influence this market on a global and regional scale

* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies

* Detailed insights on emerging regions, Therapy& Application, and competitive landscape with qualitative and quantitative information and facts.

Global Regenerative Medicine Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Inquire more or share questions if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/722408

Target Audience:

* Regenerative Medicine providers

* Traders, Importer and Exporter

* Raw material suppliers and distributors

* Research and consulting firms

* Government and research organizations

* Associations and industry bodies.

The Report Covers Exhaustive Analysis on:

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:

* Original Manufacturer,

* Therapy Supplier,

* Distributors,

* Government Body & Associations, and

* Research Institute.

Order a Copy of Global Regenerative Medicine Market Report @https://www.orianresearch.com/checkout/722408

TABLE OF CONTENT

1 Executive Summary

2 Methodology And Market Scope

3 Regenerative Medicine Market Industry Outlook

4 Regenerative Medicine Market By Product Type

5 Regenerative Medicine Market Application Type

6 Regenerative Medicine Market Regional

7 Competitive Landscape

End Of The Report

Disclaimer

Customization Service of the Report: Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Go here to see the original:
COVID 19 Impact on REGENERATIVE MEDICINE MARKET 2020 GLOBAL INDUSTRY SIZE, ANALYSIS, FUTURE GROWTH, TYPES, END-USERS, KEY PLAYERS AND REGIONAL...

Inhibition of Migration, Invasion and Drug Resistance of Pancreatic Ad | OTT – Dove Medical Press

Ezgi Kakc,1,2 Esra Aydemir,1 mer Faruk Bayrak,3 Fikrettin ahin1

1Department of Genetics and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, Istanbul 34755, Turkey; 2Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; 3Department of Medical Genetics, Yeditepe University Medical School and Yeditepe University Hospital, Istanbul 34718, Turkey

Correspondence: Ezgi Kakc Email ezgikasikci13@gmail.com

Purpose: The main purpose of this study is to demonstrate the effects of epithelial to mesenchymal transition activating transcription factor silencing (EMT-ATF silencing) on migration, invasion, drug resistance and tumor-forming abilities of various pancreatic cancer cell lines. Additionally, the contribution of small molecule inhibitors of EMT (SD-208 and CX4945) to the effects of gene silencing was evaluated. Methods: EMT activating transcription factors Snail, Slug and Twist were silenced by short hairpins on Panc-1, MIA PaCa-2, BxPC-3, and AsPC-1 pancreatic cancer cell lines. The changes in migration, invasion, laminin attachment, cancer stem-like cell properties and tumor-forming abilities were investigated. Chemosensitivity assays and small molecule inhibitors of EMT were applied to the metastatic pancreatic cancer cell line AsPC-1. Results: EMT-ATF silencing reduced EMT and stem cell-like characteristics of pancreatic cancer cell lines. Following EMT-ATF silencing amongst the four PC cell lines, AsPC-1 showed the best response and was chosen for further chemoresistance and combinational therapy applications. EMT downregulated AsPC-1 cells showed less resistance to select chemotherapeutics compared to the control group. Both small molecule inhibitors enhanced the outcomes of EMT-ATF silencing. Conclusion: Overall it was found that EMT-ATF silencing, either by EMT-ATF silencing or with the enhancement by small molecules, is a good candidate to treat pancreatic cancer since it simultaneously minimizes metastasis, stem cell properties, and drug resistance.

Keywords: pancreatic cancer, metastasis, cancer, EMT, gene therapy, anti-cancer drug

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post here:
Inhibition of Migration, Invasion and Drug Resistance of Pancreatic Ad | OTT - Dove Medical Press

Tiziana Life Sciences outlines a busy schedule for 2020 – Proactive Investors USA & Canada

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has outlined a busy schedule for 2020 after making significant clinical and pre-clinical progress with assets spanning cancers, autoimmune and inflammatory diseases.

The update was provided alongside full-year results for the 12 months to December 31, 2019.

In the outlook statement, the company said preclinical studies are ongoing for its new technology to treat coronavirus (COVID-19) infections. Its approach consists of the direct delivery of anti-IL-6 receptor monoclonal antibodies into the lungs using a handheld inhaler or nebuliser. Additionally, Tiziana said it hopes to commence a trial investigating the direct delivery of an anti-IL-6 mAb to the lungs using a portable inhaler.

Turning to Foralumab, based on successful phase I data, the company said it intends to conduct a phase II study using Crohn's Disease patients starting in the second half of this year. A study of the use of the nasally-administered drug in multiple sclerosis patients is also planned. Pre-clinical work is planned around a potential breakthrough use in Alzheimers.

For Milciclib, the company is planning a phase IIb clinical trial in HCC (liver cancer) patients with the drug being used in combination with a Tyrosine kinase inhibitors such as Regorafenib or Sorafenib.

Looking ahead, Tiziana is confident that it is well-positioned to advance these programs to their next respective value inflection points, chairman Gabriele Cerrone said in the results statement.

Tiziana also said it is continuing with the development of its StemPrint ER diagnostic tester. The stem cell-based genomic prognostic tool has been shown to be clinically superior to the standard of care, a technology called Oncotype DX, in predicting recurrence in ER+/HER2- postmenopausal breast cancer patients.

In May, the company said it was planning to spin out its StemPrintER and SPARE genomics-based personalised medicine businesses as a separate stock market quoted company.

This will allow the newly independent group to secure independent funding to accelerate the accelerated development of the StemPrintER genomic test, the group said. It will also ensure the demerged entity can focus solely on the personalised medicines market.

Turning to the financials, Tiziana, as would be expected of a company focused solely on research and development, was loss-making to the tune of 7.17mln in 2019.

R&D costs shrunk to 2.9mln from 4.1mln as the Miciclib phase IIa trial was completed.

It bolstered its cash reserves in March with a 7.8mln (U$10mln) offering of American depositary shares.

Read the original here:
Tiziana Life Sciences outlines a busy schedule for 2020 - Proactive Investors USA & Canada

9 best healthcare and medical startups in Belgium in 2020 – Silicon Canals

Health tech is an undisputed leader in the startup landscape in Belgium outranking industries such as fintech and manufacturing. There has been a persistent growth in the health tech startups in the country since the past decade. Not only startups but also in the scaleup ecosystem, healthcare is a leader in Belgium.

Mostly, a large number of Belgium health tech startups are spin-offs that have budded from research organisations. Furthermore, many initiatives and networks are also providing their support to healthcare entrepreneurship.

As Belgian health tech is doing pretty well over the years with several notable investments and innovative approaches, we at Silicon Canals have curated a list of fast-growing startups from Dealroom. Take a look!

Founder/s: NA Founded year: 2015 Funding: 15.7 million

miDiagnostics is a spin-off from imec and a research collaboration with the Johns Hopkins University in the US. The Leuven-based healthtech company is developing a new generation of disposable tests that need only drops of blood for the detection of cells, nucleic acids, proteins, and small molecules. It uses a novel silicon-based nanofluidic processor that is capable of processing the blood sample automatically sans any pumps or valves.

With miDiagnostics, there is no need for expensive and complex instrumentation to make medical decisions. The nanofluidic processor is combined with a compact reader for screening, diagnosis and monitoring of a range of health conditions including infectious ailments.

Founder/s: Dirk Loeckx, Wim Hecke Founded year: 2011 Funding: 18.4 million

Leuven-based icometrix has developed a fully automated FDA-approved and CE-certified icobrain software. Its software is already available in Europe, Brazil, Australia, Canada, and Japan. The icobrain software is deployed in over 100 hospitals and imaging centre networks all over the world and is working with the largest health tech and pharmaceutical companies as well.

icometrix touts that its icobrain software paves the way for a better and faster understanding of medical images in a more consistent and personalised manner by quantifying the volume of brain structures and abnormalities. This software is of critical importance as brain scan plays a major role in the diagnosis and treatment of various disorders in an efficient way.

Founder/s: Benedict Verhegghe, Matthieu Beule, Peter Mortier Founded year: 2009 Funding: 12.2 million

FEops based in Gent has developed FEops HEARTguide, which is a proprietary system to enhance transcatheter valve procedures depending on personalised computer simulations. The companys first product is TAVIguide, which is a CE-marked tech that can predict how a TAVI implant will interact with the patient-specific aortic anatomy and provide meaningful clinical insights.

FEops operates with the mission to create predictive, unique, and personalised computational modelling and simulation solutions that empower medical device manufacturers come up with superior products at a faster rate. These will enable physicians improve the clinical outcomes.

Founder/s: Jan Hellemans, Jo Vandesompele Founded year: 2007 Funding: 2 million

Biogazelle specialises in high-value applications that support pharmaceutical research, diagnostic test development, and clinical trials. It applies a suite of transcriptomic and genomic technologies to validate and find RNA biomarkers and assesses safety, efficacy, and toxicity.

During the COVID-19 pandemic outbreak, Biogazelle has been at the first line in the fight against the virus. It participated in a Belgian government-led consortium of academia, pharma, and biotech aimed at increasing the testing capacity in the country dramatically. The mission of this Belgian healthtech startup is to provide customised RNA gene expression services by choosing the best analytical platforms and developing data analysis software tools.

Founder/s: Jan Steyaert Founded year: 2015 Funding: 41.3 million

Confo Therapeutics is a spin-off of Vrije Universiteit Brussel (VUB) and Vlaams Instituut voor Biotechnologie (VIB). Is a drug discovery company involved in building a unique pipeline of GPCR targeted therapeutics that address unmet medical requirements. It employs its proprietary CONFO technology to lock inherently unstable functional conformations of GPRCs as a superior starting point for drug discovery.

Confo body-stabilised active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. And, recently, the company was in the headlines for appointing Paolo Therapeutics as its Chief Development Officer.

Founder/s: Etienne Sokal, John Tchelingerian Founded year: 2009 Funding: 133 million

Belgian startup Promethera Biosciences is one of the leading innovators in the world specialised in liver therapeutics. The company operates with the mission to bring life-saving treatments that will reduce the need for liver transplantation. It is one of the pioneers in the development of cell-based therapies that will provide both anti-fibrotic and immunomodulatory effects in the liver.

Promethera Biosciences lead clinical program is derived from its patented allogenic live-cell platform dubbed HepaStem. The startup has developed its cell therapy technologies using allogeneic stem and progenitor liver cells that are isolated, expanded, and purified from healthy human livers unsuitable for transplantation.

Founder/s: Denis Dufrane Founded year: 2013 Funding: 28 million

Novadip Biosciences is an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. It is transforming the lives of patients using its unique 3M3 tissue regeneration technology platform. Using its unique 3M3 tissue regeneration platform, which utilises adipose-derived stem cells within a 3-dimensional extracellular matrix, the company helps drive multiple product classes.

Novadips mission is to provide innovative solutions for patients with limited or no effective treatment options. Notably, it is a spin-off from Universit Catholique de Louvain (UCLouvain) and St. Luc University Hospital.

Founder/s: Joris Winderickx Founded year: 2002 Funding: 12 million

reMYND is a spin-off from the University of Leuven. It actively drives R&D in the field of protein misfolding diseases, among others Alzheimers disease (AD) and Parkinsons disease (PD). The company consists of two independently managed units. The Drug Discovery and Development Unit focuses on disease-modifying treatments for among others AD and PD. And, the Contract Research Unit offers extensive experience in the testing of experimental Alzheimer therapies in its unique and proprietary transgenic mouse models.

Founder/s: Nader Donzel, Rudi Pauwels Founded year: 2007 Funding: 320 million

Biocartis develops diagnostic systems to reduce the cost and improve the efficacy of personalised medical treatments. It provides next-generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry.

The companys proprietary MDx Idylla platform is a fully automated, real-time system offering accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla addresses the growing demand for personalised medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Stock photo from mustafaclk/Shutterstock

Check out the innovations that took home the Blue Tulip Awards this 2020

See the original post here:
9 best healthcare and medical startups in Belgium in 2020 - Silicon Canals

What Is the Impact of COVID-19 on 3D Cell Culture Market During Projected Period of 2020-2026? – Cole of Duty

Post COVID-19 Impact on 3D Cell Culture Market

With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues. Research Dive group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive study by our qualified team of experts.

Our study helps to acquire the following: Long-term and short-term impact of Covid-19 on the market Cascading impact of Covid-19 on 3D Cell Culture Market, due to the impact on its extended ecosystem Understanding the market behavior Pre- and Post-COVID-19 pandemic Strategy suggestions to overcome the negative impact or turn the positive impact into an opportunity Well help you fight this crisis through our business intelligence solutions.

Connect with Analyst to Reveal How COVID-19 Impacting On 3D Cell Culture Market: https://www.researchdive.com/connect-to-analyst/73

Pre COVID-19 Analysis of 3D Cell Culture Market

According to a study of Research Dive, global 3D Cell Culture market forecast shall cross $12,638.8 million by 2026, growing at a CAGR of 29.4 during forecast period.

3D Cell culture is an essential tool in clinical analysis and biological science. It has multiple applications such as in biosensors, drug screening and others. Many improvements have been made in automated high-throughput cell culture systems. Increasing demand for regenerative medicine and economic drug discovery is expected to drive the demand for the 3D cell culture market. 3D cell cultures are primarily used to observe the abnormal behavior of cells and the cell-cell interaction. Furthermore, 3D cell culture systems play a significant role in the development of precision medicine and personalized medicine. For instance, as per study of cancer researchers (University of Michigan) newly invented 3D structure could enable physicians to test medications on model tumors grown from a patients own cells. These advances are projected to boost the growth of global cell culture market. However, more complex culture system, added expenses and threats from substitutes like 2D cell cultures are projected to limit the 3D cell culture market growth.

With new advances, 3D composite scaffolds have many versatile properties. It will be tremendously useful to develop treatments for nerve disorders and spinal cord injury (SCI) by taking help of cell transplantation methodologies and biomaterials. The most remarkable advantage of 3D cell culture is, their properties can be easily adapted by modifying the structure and composition. These key factors of 3D cell culture are projected to create enormous opportunities for the growth of 3D cell culture industry.

According to Analyst Evaluation, Microchips market shall register a revenue of $2,515.5 million by the end of 2026, growing at a CAGR of 30.1% during the forecast period; this is significantly due to new advances in 3D culture organs-on-chips. Organs-on-chips allow study of human physiology and also reveal development of novel in vitro disease models. It could provide potential replacements for animals used in toxin testing and drug development. These advancements are anticipated to grow the demand of microchips in global market, and are projected to boost the global market. Scaffold-based platforms have the largest market share and this segment will register a revenue of $3,425.1 million by the end of 2026, growing at a CAGR of 28.4%. Scaffolds can be significantly used in drug development therapeutic or specialty areas; which is anticipated to fuel the of global market growth.

Download Exclusive Sample Copy of the Report at: https://www.researchdive.com/download-sample/73

Based on applications, the market is segmented into Stem Cell research, drug discovery, cancer research, and regenerative medicine. 3D cell culture market size for cancer research will generate a revenue of $4,057.1 million by 2026, growing at a CAGR of 28.5% throughout the forecast period; this is majorly due to various types of cancers such as breast cancer, lung cancer and others being dominant among the population. Cancer has a pervasive prevalence across the globe, which has led to rise in demand for cancer research, which is further attributed to boost the demand for 3D cell culture market. 3D cell culture market for regenerative medicine will register a revenue of $3,690.5 million by 2026, growing at a CAGR of 30.1%. Many developed and developing countries such as Japan is focusing more on contract manufacturing tie-ups, and continues to be a lucrative place for biotech ventures to do business. Japan is the world leader in regenerative medical products; these key strategies of the government are anticipated to spur the growth of 3D cell culture market.

3D cell culture market for biotechnology & pharmaceutical companies will register a revenue of $5,184.4 million by 2026, growing at a CAGR of 28.9% during the forecast period; this is majorly due to huge developments in the laboratory, technology and operations. Furthermore, rising pressure on sales of established treatments, rapid growth of cell therapies and focus on advanced manufacturing and technologies are the factors expected to grow the market.

North America 3D Cell Culture market size will cross $4,019.1 million by 2026, increasing at a healthy CAGR of 28.1%.

Heavy investments in research & development, high healthcare expenditure, and extensively increasing number of cancer cases are considered to be one of the driving factors that are booming the growth of North American market.

3D Cell Culture market share for Asia-Pacific region is expected to rise at a CAGR of 30.7% by generating a revenue of $3,020.7 million by 2026. The market growth in the region is increasing drug discovery initiatives among pharmaceuticals and biotechnology companies in the region. Major economies such as India, Singapore, Japan and South Korea are emphasizing more on public sector openness to partnership with established companies. For instance, leading market players such as Bayer, GlaxoSmithKline and AstraZeneca are collaborating with Singapore partners across drug discovery.

View out Trending Reports with the Impact of COVID-19: https://www.researchdive.com/covid-19-insights

The major 3D Cell Culture manufacturers include QGel SA, Hrel Corporation, SynVivo, Greiner Bio-One International, Advanced BioMatrix, Lonza, Corning Incorporated, Thermo Fisher Scientific, TissUse GmbH, 3D Biotek. Players using updated technologies for their 3D Cell Culture will have good probability of having success in the rapidly blooming market. For example, Lonza has innovated the RAFT 3D Culture System that produces hepatocytes with increased stability and stronger cytochrome responses.

Contact Us:

Mr. Abhishek Paliwal Research Dive 30 Wall St. 8th Floor, New York NY 10005 (P) + 91 (788) 802-9103 (India) +1 (917) 444-1262 (US) Toll Free : +1 -888-961-4454 Email:[emailprotected] LinkedIn:https://www.linkedin.com/company/research-dive Twitter:https://twitter.com/ResearchDive Facebook:https://www.facebook.com/Research-Dive Blog:https://www.researchdive.com/blog Follow us on:https://covid-19-market-insights.blogspot.com

Go here to see the original:
What Is the Impact of COVID-19 on 3D Cell Culture Market During Projected Period of 2020-2026? - Cole of Duty

AVITA Medical Limited Proposed Redomiciliation to the United States of America – Results of Scheme Meeting – Manchestertimes

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--Jun 15, 2020--

AVITA Medical Limited ACN 058 466 523 ( Company ) is pleased to announce that shareholders today voted in favour of the scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries ( Avita Group ) from Australia to the United States of America ( Scheme ), under which AVITA Therapeutics, Inc. ( Avita US ), a company incorporated in the State of Delaware in the United States of America, will become the parent company of the Avita Group.

Voting results of Scheme Meeting

In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the resolution to approve the Scheme (set out in the Notice of Scheme Meeting contained in Appendix F of the Scheme Booklet) was passed on a poll by the requisite majorities of shareholders.

The voting results of the Scheme Meeting are attached to this announcement.

The Scheme will not be effective unless and until:

The Second Court Hearing is scheduled to be held at 9.30am (AEST) on Monday, 22 June 2020. If the Court approves the Scheme, the Company expects to lodge the Court orders with ASIC on Tuesday, 23 June 2020.

The expected timetable for implementation of the Scheme is set out below:

Event

Indicative Date

Second Court Hearing

22 June 2020

Effective Date for the Scheme

Last day of trading of the Companys shares on the ASX

23 June 2020

Listing of Avita US on the ASX

Trading of Avita US Chess Depositary Interests ( CDIs ) commences on the ASX on a deferred settlement basis

24 June 2020

Record Date (for determining the entitlements of shareholders of the Company to Avita US shares or Avita US CDIs)

7.00pm (AEST) on 25 June 2020

Last day of trading of the Companys American Depositary Shares ( ADSs ) on NASDAQ

Last day of trading of Avita US CDIs on the ASX on a deferred settlement basis

29 June 2020

Implementation Date

The shares of the Company are transferred to Avita US and Avita US shares or Avita US CDIs are issued to eligible shareholders of the Company

29 June 2020

Listing of Avita US on NASDAQ

Trading of Avita US shares commences on NASDAQ

Promptly following the Implementation Date

Trading of Avita US CDIs commences on the ASX on a normal basis

30 June 2020

The above dates are indicative only and are subject to change. The Scheme remains subject to satisfaction or, where applicable, waiver of the conditions precedent to the Scheme (as set out in the Scheme Implementation Agreement).

Any changes to the above dates will be announced to the ASX and NASDAQ and via news release, and will also be notified on the Companys website ( http://www.avitamedical.com ).

Authorised for release by the Chief Financial Officer of AVITA Medical Limited.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device ( https://recellsystem.com/ ) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This announcement includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this announcement include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this announcement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this announcement. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this announcement speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

The following information is provided in accordance with section 251AA of the Corporations Act 2001 (Cth).

Resolution details

Instructions given to validly appointed proxies (as at proxy close)

Number of votes cast on the poll

Resolution result

Resolution

For

Against

Proxys discretion

Abstain

For

Against

Abstain*

Carried / not carried

That pursuant to and in accordance with section 411 of the Corporations Act 2001 (Cth), the scheme of arrangement proposed between the Company and the holders of its ordinary shares, the terms of which are described in the Scheme Booklet, of which the notice convening this meeting forms part, is approved, and the Board is authorised to agree to such alterations or conditions as are thought fit by the Court and, subject to approval of the Scheme by the Court, to implement the Scheme with any such alterations or conditions.

916,721,976

97.19%

20,950,290

2.22%

5,588,418

0.59%

3,786,450

N/A

926,498,581

97.75%

21,357,290

2.25%

3,876,450

N/A

Carried

Number of shareholders voting on the poll

For

Against

Abstain*

1,345

89.73%

154

View post:
AVITA Medical Limited Proposed Redomiciliation to the United States of America - Results of Scheme Meeting - Manchestertimes

Global Precision Medicine market Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Industry Updates, Future Growth, Business Prospects,…

Global Precision Medicine market is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. This analysis provides an examination of various market segments that are relied upon to observe the fastest development amid the estimated forecast frame. The report encompasses market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players. The Global Precision Medicine market analysis report also helps to know about the types of consumers, their response and views about particular products, and their thoughts for the step up of a product.

Global Precision Medicine market report provides an in-depth overview of Product Specification, technology, product type and production analysis considering major factors such as Revenue, Cost, Gross and Gross Margin. The company profiles of all the key players and brands that are dominating the Precision Medicine market with moves like product launches, joint ventures, merges and accusations which in turn is affecting the sales, import, export, revenue and CAGR values are mentioned in the report. The report is generated based on the market type, size of the organization, availability on-premises and the end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa.

Global Precision Medicine Marketto grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market are Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Download Free PDF Sample Copy of[emailprotected]http://databridgemarketresearch.com/request-a-sample/?dbmr=global-precision-medicine-market

Global Precision Medicine MarketBy Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Competitive Analysis:

The precision medicine market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Drivers

Market Restraints

Talk to The Author of Report @http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-precision-medicine-market

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Grab Your Report at an Impressive 30% Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/request-a-discount/global-precision-medicine-market

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation:

By technology:-big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Visit link:
Global Precision Medicine market Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Industry Updates, Future Growth, Business Prospects,...

Coronavirus: inside the UAE stem cell centre working to treat Covid-19 – The National

When Dr Yendry Ventura began work to set up the Abu Dhabi Stem Cell Centre in late 2018, there was, he says, nothing else "related to stem cell therapy in the emirate.

Fast forward to today and the situation has changed dramatically. After opening in December last year, the centre has already received international press coverage over to its research into a treatment for Covid-19.

Their groundbreaking work has involved taking stem cells from a patients blood and returning them, via a nebuliser, as a fine mist to the lungs.

There they help regenerate lung cells and improve the body's immune response by preventing an overreaction to the infection that can damage healthy cells.

What characterises the method, says Dr Ventura, is that very little manipulation of the cells is needed for the treatment to be effective.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

Dr Yendry Ventura

We separate a specific layer of cells from the blood, Dr Ventura told The National. Were the first one to use these cells with this route with this method.

We believe this way the cells can be aimed much better to the affected organs - the upper and lower respiratory tract.

In April, the centres efforts to develop a Covid-19 treatment led to the recovery of all 73 patients the treatment was initially trialled on. A quarter had been in intensive care.

The results appeared so promising that this month the centre secured intellectual property rights to the technique, allowing the treatment to be widely licensed, including to facilities abroad.

The ongoing work exemplifies how the centres specialists have been able to apply their expertise to help in a time of crisis, Dr Ventura said.

But the new research is a departure from the facilitys usual purpose, which involves developing cutting-edge stem cell treatments for conditions such as cancer and heart disease.

Stem cells were first extracted from humans and grown in laboratories less than a quarter of a century ago.

The human body is mostly made of specialised cell types, such as heart muscle cells, kidney cells or nerve cells, all of which have a particular form related to their function.

Stem cells, however, have not yet undergone the process of developing into a specialised cell type, and are able to be manipulated to perform a specific function.

In adults, stem cells are found in tissues including fat and bone marrow, and these can be turned into cell types.

One technique that the Abu Dhabi Stem Cell Centre plans to implement is haematopoietic stem cell transplantation, which involves stem cells being removed from an individual who is due to have cancer treatment.

The cells are then processed in a laboratory and injected into the patient after they have undergone chemotherapy or radiotherapy.

In this way, they can replace stem cells destroyed by the treatment, allowing a patient to tolerate a higher dose of therapy.

Dr Ventura says that similar treatments were applicable to most cancers of the blood as well as cancers that produce solid tumours.

There are many of these therapies still in research stage, but if you conquer this research, you can have a programme in which you can ... treat many kinds of cancers at the same time in one centre, he said.

The reality is that cell therapy is curing cancer We need to improve this therapy and make it available for many other people.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

You can create in the future, if you have the right technologies, even artificial organs.

Set up with private sector funding in collaboration with the UAE authorities, the Abu Dhabi Stem Cell Centre works closely with experts at Sheikh Khalifa Medical City.

But the institution is keen to forge further partnerships with both public and private sector medical institutions.

Currently, it operates seven days a week and has more than 100 staff, including nurses, technicians and doctors who specialise in immunology, haematology, pathology, orthopaedics, urology and radiology.

In another initiative, the facility has recently begun running Minimal Residual Disease tests, which look at how many malignant cells remain in a patients blood or bone marrow.

These tests are useful for people with a variety of blood cancers, including lymphoma, leukaemia and myeloma. But they require fresh samples from the patient, so the lack of UAE testing facilities has, until now, required patients to travel abroad.

We try to implement the tests here in the Abu Dhabi Stem Cell Centre so that the patient does not need to travel anymore, said Dr Ventura.

Updated: June 16, 2020 02:01 PM

Read the original post:
Coronavirus: inside the UAE stem cell centre working to treat Covid-19 - The National

Safe to Skip Radiotherapy With Negative PET in Hodgkin Lymphoma – Medscape

The majority of patients with early stage unfavorable Hodgkin lymphoma respond well enough to a current standard regimen of 4 cycles of chemotherapy, and can skip the additional radiotherapy that is normally included in the combined modality treatment, say experts reporting the final results from an international phase 3 randomized trial dubbed HD17.

"Most patients with this disease will not need radiotherapy any longer," concluded first author Peter Borchmann, MD, assistant medical director in the Department of Hematology/Oncology at the University Hospital of Cologne, Germany.

Borchmann was speaking online as part of the virtual edition of the European Hematology Association (EHA) 25th Annual Congress 2020.

"Importantly, the mortality of patients with early stage unfavorable Hodgkin lymphoma in the HD17 study did not differ from the normal healthy German population, and this is the first time we have had this finding in one of our studies," he emphasized.

Borchmann added that positron emission tomography (PET) imaging is key in deciding which patients can skip radiation.

"We conclude from the HD17 trial that the combined modality concept can and should be replaced by a PET-guided omission of radiotherapy for patients with newly diagnosed early stage unfavorable Hodgkin lymphoma," he said.

"The vast majority of early stage unfavorable Hodgkin lymphoma patients can be treated with the brief and highly effective 2+2 chemotherapy alone," he added.

Therefore, he continued, "PET-guided 2+2 chemotherapy is the new standard of care for the German Hodgkin study group," which conducted the trial.

The use of both chemotherapy and radiation has long been a standard approach to treatment, and this combined modality treatment is highly effective, Borchmann explained. But it can cause long-term damage, and the known longer-term negative effects of radiotherapy, such as cardiovascular disease and second malignancies, are a particular concern because patients with early stage Hodgkin lymphoma are relatively young, with a median age of around 30 years at disease onset.

An expert approached for comment said that the momentum to skip radiotherapy when possible is an ongoing issue, and importantly, this study adds to those efforts.

"The treatment of Hodgkin lymphoma has moved for many years now to less radiation therapy, and this trend will continue with the results of this study," commented John G. Gribben, MD, director of the Stem Cell Transplantation Program and medical director of the North East London Cancer Research Network Centre at Barts Cancer Center of Excellence and The London School of Medicine, UK.

"We have moved to lower doses and involved fields with the intent of decreasing toxicity, and particularly long-termtoxicity from radiotherapy," he told Medscape Medical News.

For the multicenter, phase 3 HD17 trial, Borchmann and colleagues turned to PET to identify patients who had and had not responded well to chemotherapy (PET-negative and PET-positive) and to determine if those who had responded well could safely avoid radiotherapy without compromising efficacy.

We wanted to determine if we could reduce the treatment intensity by omission of radiotherapy in patients who respond very well to the systemic treatment, so who have a complete metabolic remission after the chemotherapy, Borchmann said.

The 2+2 treatment approach includes 2 cycles of eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and 2 subsequent cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).

The trial enrolled 1100 patients with newly diagnosed Hodgkin lymphoma between January 2012 and March 2017. Of these, 979 patients had confirmed PET results, with 651 (66.5%) found to be PET-negative, defined as having a Deauville score (DS) of less than 3 (DS3); 238 (24.3%) were DS3 and 90 (9.2%) were DS4.

The study met its primary endpoint of noninferiority in progression-free survival (PFS) at 5 years, with a PFS of 95.1% in the PET-guided group (n = 447) compared with 97.3% in the standard combined-modality treatment group (n = 428), over a median observation time of 45 months, for a difference of 2.2% (P = .12).

"We found that the survival levels were very high and we can safely conclude the noninferiority of the PET-guided approach in PET-negative patients," Borchmann said.

A further analysis showed that the 597 PET-negative patients who did not receive radiotherapy due to their PET status had 5-year PFS that was noninferior to the combined modality group (95.9% vs 97.7%, respectively; P = .20).

And among 646 patients who received the 2+2 regimen plus radiotherapy, of thoseconfirmed as PET-positive (n = 328), the estimated 5-year PFS was significantly lower (94.2%) compared with those determined to be PET-negative (n = 318; 97.6%; hazard ratio, 3.03).

A cut-off of DS4 for positivity was associated with a stronger effect, with a lower estimated 5-year PFS of 81.6% vs 98.8% for DS3 patients and 97.6% for DS < 3 (P < .0001).

"Only DS4 has a prognostic impact, but not DS3," Borchmann said. "DS4 positivity indicates a relevant risk for treatment failure, however, there are few patients in this risk group (9.2% in this trial)."

The 5-year overall survival rates in an intent-to-treat analysis were 98.8% in the standard combined modality group and 98.4% in the PET-guided group.

With a median observation time of 47 months, there have been 10 fatal events in the trial out of 1100 patients, including two Hodgkin lymphoma-related events and one treatment-related death.

"Overall, Hodgkin lymphoma or treatment-related mortality rates were extremely low," Borchmann said.

The study was funded by Deutsche Krebshilfe. Borchmann and Gribben have reported no relevant financial relationships.

EHA 2020 Congress. Presented June 12, 2020. Abstract S101.

For more from Medscape Oncology, join us on Twitter and Facebook.

View post:
Safe to Skip Radiotherapy With Negative PET in Hodgkin Lymphoma - Medscape